Gebro Pharma has concluded the 2025 fiscal year with a turnover of 112 million euros, representing a 2% increase compared to the previous year, as the company reported this Thursday in a statement.
The pharmaceutical company indicated that it closed the year "confirming positive evolution, sustaining its level of activity and generating favorable results in a demanding environment". The revenue growth has been supported, mainly, by the good performance of its commercial products and by "responsible cost management".
The company has emphasized that, throughout the past year, it added two new medications to its portfolio, designed with the dual objective of responding to specific patient needs and providing value to public health systems.
At the same time, the company has explained that it "is studying acquisitions of products in the areas of Autoimmune Diseases, Pain, Respiratory, and Urology, and also in some products in the Hospital field", with a view to reinforcing its presence in these therapeutic segments.